Robert W. Baird restated their outperform rating on shares of Gilead Sciences, Inc. (NASDAQ:GILD) in a research note published on Tuesday morning. The brokerage currently has a $87.00 price objective on the biopharmaceutical company’s stock.

Other equities analysts also recently issued research reports about the stock. Jefferies Group LLC reissued a hold rating and issued a $80.00 price objective on shares of Gilead Sciences in a research note on Tuesday, July 11th. Credit Suisse Group reissued an outperform rating and issued a $85.00 price objective (up previously from $79.00) on shares of Gilead Sciences in a research note on Tuesday. Maxim Group restated a hold rating on shares of Gilead Sciences in a research report on Wednesday, May 3rd. BMO Capital Markets restated a hold rating and issued a $76.00 price target (up from $75.00) on shares of Gilead Sciences in a research report on Wednesday, May 3rd. Finally, Barclays PLC restated an overweight rating and issued a $85.00 price target on shares of Gilead Sciences in a research report on Wednesday, May 3rd. Eleven analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus target price of $80.83.

Gilead Sciences (GILD) opened at 75.74 on Tuesday. The company has a 50-day moving average price of $72.97 and a 200-day moving average price of $68.86. The company has a market capitalization of $98.91 billion, a price-to-earnings ratio of 8.23 and a beta of 1.21. Gilead Sciences has a one year low of $63.76 and a one year high of $82.07. Gilead Sciences also was the target of some unusual options trading activity on Monday. Stock investors bought 19,878 put options on the stock. This is an increase of approximately 209% compared to the average daily volume of 6,434 put options.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.11 by $0.45. The business had revenue of $7.14 billion during the quarter, compared to the consensus estimate of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The firm’s revenue was down 8.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.08 EPS. Equities research analysts anticipate that Gilead Sciences will post $8.73 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Gilead Sciences, Inc. (GILD) Given “Outperform” Rating at Robert W. Baird” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://www.thecerbatgem.com/2017/08/30/gilead-sciences-inc-gild-given-outperform-rating-at-robert-w-baird.html.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 28th. Stockholders of record on Friday, September 15th will be paid a $0.52 dividend. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.75%. Gilead Sciences’s payout ratio is 22.58%.

In related news, EVP Gregg H. Alton sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $71.06, for a total transaction of $355,300.00. Following the completion of the transaction, the executive vice president now owns 102,988 shares of the company’s stock, valued at $7,318,327.28. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Gregg H. Alton sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 1st. The shares were sold at an average price of $75.88, for a total transaction of $1,138,200.00. Following the transaction, the executive vice president now directly owns 106,113 shares of the company’s stock, valued at approximately $8,051,854.44. The disclosure for this sale can be found here. Insiders sold 206,666 shares of company stock valued at $15,223,184 in the last quarter. Corporate insiders own 1.30% of the company’s stock.

Institutional investors have recently modified their holdings of the stock. Hall Laurie J Trustee boosted its position in shares of Gilead Sciences by 20.0% in the first quarter. Hall Laurie J Trustee now owns 1,500 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 250 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. boosted its position in shares of Gilead Sciences by 583.3% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 1,400 shares in the last quarter. Dubuque Bank & Trust Co. boosted its position in shares of Gilead Sciences by 19.4% in the first quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 267 shares in the last quarter. Penserra Capital Management LLC boosted its position in shares of Gilead Sciences by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 144 shares in the last quarter. Finally, Webster Bank N. A. boosted its position in shares of Gilead Sciences by 51.7% in the first quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock valued at $125,000 after buying an additional 624 shares in the last quarter. 74.04% of the stock is owned by institutional investors.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.